Use of Clozapine for Resolving Lamotrigine-Induced Skin Lesions Caused by Schizophrenia Treatment

Tsai, Lee-Hou

doi:10.24869/psyd.2019.362

Cited by 2 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…52 However, aiming for higher adherence and less sedation during the day, there seems to be a shift towards QD dosing of clozapine at the end of the day. 53 In practice, clozapine concentrations measured in samples taken twelve hours post-dose are set against the therapeutic window that has been based on clozapine trough concentrations from divided dose regimens of clozapine. This assumes the same concentration-effect relation as well as similar pharmacokinetics at QD and BID dosing, although this has not been studied before.…”

Section: Therapeutic Drug Monitoring and Pharmacokinetics Of Clozapinementioning

confidence: 99%

“…The mother had been using clozapine during gestation and the father had been dependent on alcohol. Several case reports describe normal neurodevelopment after different follow-up periods, 33,39,41,44,47,50,53,54,57 but these reports are generally of limited quality and, again, it is not known how the neurodevelopment of these infants had been assessed. In summary, it remains unclear whether early developmental exposure to clozapine results in permanent changes in the brain that affect cognitive function or behaviour in both the short and long term.…”

Section: Neurodevelopment (Table 4)mentioning

confidence: 99%

“…A number of case reports and case series 29,30,32,46,48,54,56 report various malformations but often lack information regarding possible confounders, and there does not seem to be a clear pattern of malformations. Moreover, there are at least as many reports 18,24,31,33,35,41,43,44,47,50,53,54,57 describing uncomplicated pregnancies and healthy offspring without malformations after foetal exposure to clozapine, of which one uncomplicated triplet 36 and one twin pregnancy. 41 In summary, although the available data are limited in terms of quality and quantity, clozapine does not appear to be a teratogenic agent.…”

Section: Congenital Malformations (Table 4)mentioning

confidence: 99%

See 2 more Smart Citations

Supporting successful clozapine treatment

Beex-Oosterhuis¹

View full text Add to dashboard Cite

The overall objective of this thesis is to support successful clozapine treatment, by firstly expanding the knowledge on the predictability of early clozapine discontinuation, secondly investigating the necessity of clozapine discontinuation due to (intended) pregnancy, and thirdly expanding the knowledge on therapeutic drug monitoring (TDM) of clozapine in light of once-daily (QD) dosing and protein binding, as well as in light of possible pitfalls in the interpretation of these TDM results. In chapter 2.1 a prediction model was developed for unsuccessful clozapine treatment one year after the drug was first dispensed by a community pharmacy. Unsuccessful clozapine treatment was defined as the absence of current insurance claims for clozapine treatment 365 days after the index date. In 20.4% clozapine treatment was unsuccessful 1 year after the index date. Unsuccessful treatment was more common among outpatient starters than among inpatient starters. The number of variables needed to predict as much as 30% or 68% of the variability in unsuccessful clozapine treatment was too large for a simple prediction model. Disproportionality in case safety reports on adverse pregnancy outcomes between clozapine and other antipsychotics (OAP) used during pregnancy was determined in chapter 3.1. Overall, no signal of disproportionate reporting associating clozapine with the studied adverse pregnancy outcomes was found. Chapter 3.2 provides a critical appraisal of the available evidence related to the safety of clozapine for schizophrenia during pregnancy and lactation. Data on perinatal clozapine exposure are of limited quality and quantity. Data thus far do not support that clozapine is teratogenic, increases the risk of stillbirth, abortion, or foetal disorders, nor that it increases the risk of delivery complications or premature birth. Information about clozapine exposure through breast milk is scarce. In chapter 4.1, we determined whether the pharmacokinetics of clozapine and norclozapine with QD use are similar to twice-daily (BID) use. Dosing regimen did not affect any of the pharmacokinetic parameters of clozapine and norclozapine. Clozapine concentrations sampled in the morning with QD use are markedly different from its trough concentrations and higher than if the same daily dose had been used in two divided doses. The implications of this on clozapine’s therapeutic window at QD dosing is yet unknown. In chapter 4.2, we investigated whether protein binding of clozapine and norclozapine becomes saturated at higher concentrations. Secondly, we investigated the correlation between unbound clozapine and norclozapine fractions and alpha-1 acid glycoprotein concentrations. Clozapine and norclozapine concentrations correlated well with its unbound concentrations. The dosing regimen did not affect the relation between total clozapine and norclozapine concentrations and its unbound fractions. A moderate (clozapine) and small (norclozapine) correlation were found between AGP-concentrations and unbound fractions of clozapine and norclozapine. Chapter 4.3 describes the hurdles to be taken when developing a method for quantification of the unbound concentrations of clozapine and norclozapine in serum, using ultrafiltration (UF). This study demonstrates that the choice of the ultrafilter is a crucial part of the development of a method to measure unbound concentrations using UF. Adequate control of the factors influencing the NSA is essential, as well as factors influencing the stability of the protein-drug complex. The study in chapter 4.4 assessed whether clozapine concentrations measured in plasma collected with tubes containing ethylenediaminetetraacetic (EDTA) and lithium-heparin (LH) as anticoagulants are comparable to clozapine concentrations measured in serum. The use of LH-derived plasma samples for therapeutic drug monitoring of clozapine may lead to different clinical interpretations than when using serum samples. Therefore, interchangeable use of LH-derived plasma and serum samples to measure clozapine levels in clinical practice is not recommended. In chapter 5, the findings of this thesis were put into a broader perspective.

show abstract

Section: Therapeutic Drug Monitoring and Pharmacokinetics Of Clozapinementioning

confidence: 99%